These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 18330936)

  • 41. Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells.
    Tyagi AK; Agarwal C; Chan DC; Agarwal R
    Oncol Rep; 2004 Feb; 11(2):493-9. PubMed ID: 14719089
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Enhanced therapeutic effects of combined chemotherapeutic drugs and midkine antisense oligonucleotides for hepatocellular carcinoma.
    Dai LC; Wang X; Yao X; Lu YL; Ping JL; He JF
    World J Gastroenterol; 2007 Apr; 13(13):1989-94. PubMed ID: 17461503
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Ethanolic Extract of Taiwanofungus camphoratus (Antrodia camphorata) Induces Cell Cycle Arrest and Enhances Cytotoxicity of Cisplatin and Doxorubicin on Human Hepatocellular Carcinoma Cells.
    Lin LT; Tai CJ; Su CH; Chang FM; Choong CY; Wang CK; Tai CJ
    Biomed Res Int; 2015; 2015():415269. PubMed ID: 26557666
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inhibition of the JNK signaling pathway increases sensitivity of hepatocellular carcinoma cells to cisplatin by down-regulating expression of P-glycoprotein.
    Liu XY; Liu SP; Jiang J; Zhang X; Zhang T
    Eur Rev Med Pharmacol Sci; 2016; 20(6):1098-108. PubMed ID: 27049263
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combination of arsenic trioxide and chemotherapy in small cell lung cancer.
    Zheng CY; Lam SK; Li YY; Fong BM; Mak JC; Ho JC
    Lung Cancer; 2013 Nov; 82(2):222-30. PubMed ID: 24041618
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The synergistic and antagonistic effects of cytotoxic and biological agents on the in vitro antitumour effects of suramin.
    Lopez Lopez R; van Rijswijk RE; Wagstaff J; Pinedo HM; Peters GJ
    Eur J Cancer; 1994; 30A(10):1545-9. PubMed ID: 7833116
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Coadministration of sorafenib and cisplatin inhibits proliferation of hepatocellular carcinoma HepG2 cells in vitro].
    Chen FS; Cui YZ; Luo RC; Wu J; Zhang H
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(9):1684-7. PubMed ID: 18819900
    [TBL] [Abstract][Full Text] [Related]  

  • 48. EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer.
    Huether A; Höpfner M; Baradari V; Schuppan D; Scherübl H
    Biochem Pharmacol; 2005 Nov; 70(11):1568-78. PubMed ID: 16226226
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Targeted hepatocellular carcinoma therapy: transferrin modified, self-assembled polymeric nanomedicine for co-delivery of cisplatin and doxorubicin.
    Zhang X; Li J; Yan M
    Drug Dev Ind Pharm; 2016 Oct; 42(10):1590-9. PubMed ID: 26942448
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Synergistic antitumoral activity and induction of apoptosis by novel pan Bcl-2 proteins inhibitor apogossypolone with adriamycin in human hepatocellular carcinoma.
    Mi JX; Wang GF; Wang HB; Sun XQ; Ni XY; Zhang XW; Tang JM; Yang DJ
    Acta Pharmacol Sin; 2008 Dec; 29(12):1467-77. PubMed ID: 19026166
    [TBL] [Abstract][Full Text] [Related]  

  • 51. PJ34, an inhibitor of PARP-1, suppresses cell growth and enhances the suppressive effects of cisplatin in liver cancer cells.
    Huang SH; Xiong M; Chen XP; Xiao ZY; Zhao YF; Huang ZY
    Oncol Rep; 2008 Sep; 20(3):567-72. PubMed ID: 18695907
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effect of doxorubicin on MEK-ERK signaling predicts its efficacy in HCC.
    Choi J; Yip-Schneider M; Albertin F; Wiesenauer C; Wang Y; Schmidt CM
    J Surg Res; 2008 Dec; 150(2):219-26. PubMed ID: 18468633
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Triphala, Ayurvedic formulation for treating and preventing cancer: a review.
    Baliga MS
    J Altern Complement Med; 2010 Dec; 16(12):1301-8. PubMed ID: 21138390
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combination of cyclooxygenase-2 inhibitor and doxorubicin increases the growth inhibition and apoptosis in human hepatocellular carcinoma cells.
    Pan YY; Xu SP; Jia XY; Xu HQ; Zhang Y; Rui LX; Wei W
    Exp Oncol; 2007 Mar; 29(1):23-9. PubMed ID: 17431384
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Study of pharmacodynamic interaction of Phyllanthus emblica extract with clopidogrel and ecosprin in patients with type II diabetes mellitus.
    Fatima N; Pingali U; Muralidhar N
    Phytomedicine; 2014 Apr; 21(5):579-85. PubMed ID: 24291054
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synergism of cisplatin-oleanolic acid co-loaded calcium carbonate nanoparticles on hepatocellular carcinoma cells for enhanced apoptosis and reduced hepatotoxicity.
    Khan MW; Zhao P; Khan A; Raza F; Raza SM; Sarfraz M; Chen Y; Li M; Yang T; Ma X; Xiang G
    Int J Nanomedicine; 2019; 14():3753-3771. PubMed ID: 31239661
    [No Abstract]   [Full Text] [Related]  

  • 57. Cytotoxic and apoptotic-inducing effects of purple rice extracts and chemotherapeutic drugs on human cancer cell lines.
    Banjerdpongchai R; Wudtiwai B; Sringarm K
    Asian Pac J Cancer Prev; 2014 Jan; 14(11):6541-8. PubMed ID: 24377565
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A novel cell cycle blocker extracted from Stellera chamaejasme L. inhibits the proliferation of hepatocarcinoma cells.
    Kan XX; Li Q; Chen X; Wang YJ; Li YJ; Yang Q; Xiao HB; Wang ZX; Chen Y; Weng XG; Cai WY; Zhu XX
    Oncol Rep; 2016 Jun; 35(6):3480-8. PubMed ID: 27109908
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Indian medicinal plants as a reservoir of protective phytochemicals.
    Arora S; Kaur K; Kaur S
    Teratog Carcinog Mutagen; 2003; Suppl 1():295-300. PubMed ID: 12616620
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oleuropein potentiates anti-tumor activity of cisplatin against HepG2 through affecting proNGF/NGF balance.
    Sherif IO; Al-Gayyar MMH
    Life Sci; 2018 Apr; 198():87-93. PubMed ID: 29476769
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.